Join
Live feed
·
PRReleasevia Quantisnow
Kalaris Therapeutics Inc. logo

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

ByQuantisnow·Wall Street's wire, on your screen.
KLRS· Kalaris Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KLRS (Kalaris Therapeutics Inc.) and more on Quantisnow.